Verition Fund Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.73M Buy
61,700
+13,500
+28% +$359K 0.01% 1090
2025
Q4
$1.2M Sell
48,200
-33,100
-41% -$835K ﹤0.01% 2010
2025
Q3
$2.07M Buy
81,300
+60,400
+289% +$1.49M 0.01% 1947
2025
Q2
$507K Buy
+20,900
New +$487K ﹤0.01% 2934
2024
Q3
Sell
-16,200
Closed -$453K 3445
2024
Q2
$453K Buy
+16,200
New +$446K ﹤0.01% 2101
2024
Q1
Sell
-17,300
Closed -$498K 2929
2023
Q4
$498K Hold
17,300
﹤0.01% 1520
2023
Q3
$574K Buy
+17,300
New +$612K 0.01% 1363
2022
Q2
Sell
-9,200
Closed -$476K 2890
2022
Q1
$476K Buy
+9,200
New +$477K 0.01% 1928
2021
Q1
Sell
-69,900
Closed -$2.57M 1719
2020
Q4
$2.57M Buy
+69,900
New +$2.56M 0.02% 325

Other funds holding PFE

Verition Fund Management's PFE Position: Q1 2026 in Review

Verition Fund Management sold out of Pfizer (PFE) in Q1 2026, closing a stake of 248,837 shares — an estimated $6.62M sold.

Verition Fund Management first reported a position in PFE in Q3 2013 and held it in 37 quarters. The position peaked at $9.32M in Q3 2025. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Verition Fund Management reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 248,837 Pfizer shares in Q1 2026, an estimated $6.62M.
  • Verition Fund Management first reported a position in Pfizer in Q3 2013 and held it in 37 quarters.
  • Verition Fund Management's Pfizer position peaked at $9.32M in Q3 2025.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.